文献速递支持与姑息治疗

癌症患者COVID-19相关住院和死亡的风险因素:美国国家癌症研究所癌症患者COVID-19研究(NCCAPS)

Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS).
PubMed 文献 · JAMA Oncol · 2025-01-01

NCCAPS前瞻性纵向自然史队列研究纳入1572例成人癌症患者,分析COVID-19相关住院和死亡的风险因素。多变量分析显示化疗(HR 1.97)及卒中、心房颤动或肺栓塞病史(HR 1.78)与住院风险升高相关,感染前接种疫苗与住院风险降低相关(HR 0.52)。90天COVID-19相关死亡率为3.0%,随访期间共1739次癌症治疗中断,其中881次(50.7%)归因于COVID-19。

要点

  • 化疗(HR 1.97;95%CI 1.52-2.54)及卒中、心房颤动或肺栓塞病史(HR 1.78;95%CI 1.33-2.38)与COVID-19住院风险升高相关。
  • 感染前接种SARS-CoV-2疫苗与住院风险降低相关(HR 0.52;95%CI 0.38-0.70)。
  • 90天COVID-19相关死亡率为3.0%,随访期间881次(50.7%)治疗中断归因于COVID-19。

核心结论

  • 这项前瞻性队列研究结果显示,COVID-19对癌症患者有显著影响,包括住院、治疗中断和死亡。

研究设计与样本

  • 美国国家癌症研究所癌症患者COVID-19研究(NCCAPS)为前瞻性纵向自然史队列研究,旨在考察COVID-19对癌症患者的影响。
  • 入组条件为在首次SARS-CoV-2检测阳性后14天内、正在接受癌症积极治疗或曾接受干细胞/骨髓移植或CAR T细胞治疗的成人患者。
  • 共纳入1572例符合条件的成人患者,中位(范围)年龄60(18-93)岁,女性840例(53.4%);1066例(67.8%)为实体瘤,其中683例(64.0%)为转移性疾病。
  • 实体瘤中以乳腺癌(252例[23.6%])和肺癌(148例[13.9%])最常见;入组时1013例(64.4%)未接种SARS-CoV-2疫苗。
  • 统计分析于2024年9月至2025年4月进行,主要终点为首次SARS-CoV-2检测阳性后30天和90天内因COVID-19住院或死亡。

主要发现

  • 90天COVID-19相关死亡率为3.0%,后续时间点未再升高。
  • 前90天COVID-19特异性死亡的累积发生率在淋巴瘤患者中最高,急性白血病和肺癌患者居中,其他实体瘤和其他血液系统肿瘤患者最低。
  • 多变量分析中,接受化疗与住院风险升高相关(HR 1.97;95%CI 1.52-2.54)。
  • 基线有卒中、心房颤动或肺栓塞病史与住院风险升高相关(HR 1.78;95%CI 1.33-2.38)。
  • SARS-CoV-2感染前接种疫苗与住院风险降低相关(HR 0.52;95%CI 0.38-0.70);随访超过2年共发生1739次癌症治疗中断,其中881次(50.7%)归因于COVID-19,多数中断发生在前30天内。

关键数值与推荐

  • COVID-19严重程度定义为首次SARS-CoV-2检测阳性后30天和90天内因COVID-19住院或死亡。
  • 多变量回归采用比例风险模型和病因特异性风险模型分析COVID-19特异性住院和死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Retrospective case series have identified having cancer and receiving treatment for cancer as risk factors for inferior COVID-19 outcomes. OBJECTIVE: To determine risk factors for hospitalization and death in patients with cancer with COVID-19 infection. DESIGN, SETTING, AND PARTICIPANTS: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) is a prospective longitudinal natural history cohort study examining the impact of COVID-19 on patients with cancer. Adults were eligible within 14 days of an initial positive SARS-CoV-2 test result if they were receiving active treatment for cancer or had prior stem cell/bone marrow transplant or CAR T-cell treatment. The statistical analysis took place between September 2024 and April 2025. MAIN OUTCOMES AND MEASURES: The primary objective of the study was to determine patient factors, therapy types, and cancer types associated with COVID-19 severity, defined as hospitalization for or death from COVID-19 within 30 and 90 days after the first positive SARS-CoV-2 test result. Multivariable regressions were performed for COVID-19-specific hospitalization and mortality (proportional hazard and cause-specific hazard models). RESULTS: Of 1572 eligible adult patients (median [range] age, 60 [18-93] years; 840 female [53.4%]), 1066 (67.8%) had a solid tumor, with 683 (64.0%) having metastatic disease; breast (252 [23.6%]) and lung cancer (148 [13.9%]) were most common. At enrollment, 1013 patients (64.4%) were unvaccinated for SARS-CoV-2. COVID-19-related mortality at 90 days was 3.0% and did not increase at subsequent time points. The cumulative incidence of COVID-19-specific death in the first 90 days was highest in patients with lymphoma, intermediate in patients with acute leukemia and lung cancer, and lowest in patients with other solid tumors and other hematologic cancers. In multivariable analysis, receipt of chemotherapy (hazard ratio [HR], 1.97; 95% CI, 1.52-2.54) and baseline history of stroke, atrial fibrillation, or pulmonary embolism (HR, 1.78; 95% CI, 1.33-2.38) were associated with a higher risk of hospitalization. Vaccination prior to SARS-CoV-2 infection was associated with a lower risk of hospitalization (HR, 0.52; 95% CI, 0.38-0.70). Over 2 years of follow-up, there were 1739 cancer treatment disruptions, of which 881 (50.7%) were attributed to COVID-19, with most disruptions occurring within the first 30 days. CONCLUSIONS AND RELEVANCE: The results of this prospective cohort study showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Rini BI, Best AF, Bowman MD, et al. Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS). JAMA Oncol. 2025. PMID: 40674082. doi:10.1001/jamaoncol.2025.2010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。